nitrendipine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
calcium channel blockers, nifedipine derivatives	1947	39562-70-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nitrendipine nitrendipin nitrepin	A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. Molecular weight: 360.37 Formula: C18H20N2O6 CLOGP: 3.73 LIPINSKI: 0 HAC: 8 HDO: 1 TPSA: 107.77 ALOGS: -4.41 ROTB: 7

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.92 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	16.50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	6.10 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	25 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	8.20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1985	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
General physical health deterioration	76.87	33.51	55	2200	115714	46568093
Antinuclear antibody negative	71.35	33.51	12	2243	228	46683579
Hypertension	68.34	33.51	64	2191	196292	46487515
Herpes simplex reactivation	66.49	33.51	12	2243	348	46683459
Coombs positive haemolytic anaemia	65.53	33.51	12	2243	378	46683429
Fall	58.04	33.51	75	2180	329022	46354785
Product prescribing error	57.37	33.51	25	2230	20022	46663785
Gastritis haemorrhagic	50.89	33.51	12	2243	1314	46682493
Antiphospholipid syndrome	47.85	33.51	12	2243	1700	46682107
Complex regional pain syndrome	45.61	33.51	12	2243	2054	46681753
Hypertensive angiopathy	44.18	33.51	7	2248	90	46683717
Anxiety disorder	43.62	33.51	13	2242	3498	46680309
Hypertensive crisis	39.01	33.51	17	2238	13598	46670209
Premature baby	37.37	33.51	18	2237	18094	46665713
Lymphopenia	37.11	33.51	17	2238	15276	46668531
Hyperlipidaemia	36.98	33.51	18	2237	18521	46665286
Syncope	36.01	33.51	34	2221	104769	46579038
Erysipelas	34.93	33.51	13	2242	6925	46676882

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product prescribing error	73.18	26.80	31	1981	16702	29933764
Syncope	60.40	26.80	48	1964	84855	29865611
Dizziness	59.56	26.80	69	1943	194840	29755626
Osteochondrosis	38.01	26.80	9	2003	719	29949747
Postrenal failure	36.94	26.80	8	2004	427	29950039
General physical health deterioration	36.59	26.80	39	1973	99905	29850561

Pharmacologic Action:

Source	Code	Description
ATC	C08CA08	CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives
ATC	C09BB06	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and calcium channel blockers
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002121	Calcium Channel Blockers
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D014665	Vasodilator Agents
CHEBI has role	CHEBI:35620	vasodilator
CHEBI has role	CHEBI:35674	antihypertensive
CHEBI has role	CHEBI:38215	calcium channel blockers

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.37	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Voltage-dependent L-type calcium channel subunit alpha-1D	Ion channel	Q01668	CAC1D_HUMAN	GATING INHIBITOR	IC50	8.40		IUPHAR	IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1C	Ion channel	Q13936	CAC1C_HUMAN	BLOCKER				UNKNOWN	SCIENTIFIC LITERATURE
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	6.52		DRUG MATRIX
Cytochrome P450 2C19	Enzyme	P33261	CP2CJ_HUMAN		IC50	5.52		DRUG MATRIX
Voltage-dependent T-type calcium channel subunit alpha-1H	Ion channel	O95180	CAC1H_HUMAN		IC50	5.06		WOMBAT-PK
Transthyretin	Secreted	P02766	TTHY_HUMAN		IC50	5.92		WOMBAT-PK
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	4.44		CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	5		CHEMBL
Voltage-dependent calcium channel gamma-1 subunit	Ion channel	Q06432	CCG1_HUMAN					WOMBAT-PK
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.08		WOMBAT-PK
Voltage-dependent L-type calcium channel subunit alpha-1F	Ion channel	O60840	CAC1F_HUMAN	GATING INHIBITOR	IC50	6		IUPHAR
Intermediate conductance calcium-activated potassium channel protein 4	Ion channel	O15554	KCNN4_HUMAN	BLOCKER	IC50	7.60		IUPHAR
Platelet-activating factor receptor	GPCR		PTAFR_CAVPO		Ki	4.13		CHEMBL
Adenosine receptor A2a	GPCR		AA2AR_RAT		Ki	4.64		CHEMBL
Adenosine receptor A1	GPCR		AA1R_RAT		Ki	5.05		CHEMBL
Voltage-dependent L-type calcium channel subunit alpha-1C	Ion channel		CAC1C_RAT	GATING INHIBITOR	IC50	6		IUPHAR
Voltage-dependent L-type calcium channel subunit alpha-1S	Ion channel		CAC1S_RAT	GATING INHIBITOR	IC50	6		IUPHAR

External reference:

ID	Source
N0000167238	NUI
D00629	KEGG_DRUG
C0028127	UMLSCUI
CHEBI:7582	CHEBI
CHEMBL251230	ChEMBL_ID
CHEMBL268609	ChEMBL_ID
CHEMBL475534	ChEMBL_ID
D009568	MESH_DESCRIPTOR_UI
DB01054	DRUGBANK_ID
2334	IUPHAR_LIGAND_ID
4739	INN_ID
9B627AW319	UNII
4507	PUBCHEM_CID
7441	RXNORM
005383	NDDF
444757009	SNOMEDCT_US

Pharmaceutical products:

None